Old Web
English
Sign In
Acemap
>
authorDetail
>
Sohail Mulla
Sohail Mulla
Genentech
Internal medicine
Oncology
Medicine
Atezolizumab
Pathology
2
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.
2020
Journal of Clinical Oncology
Karl D. Lewis
Caroline Robert
Paolo A. Ascierto
Daniil Stroyakovskiy
Helen Gogas
Svetlana Protsenko
Rodrigo Perez Pereira
Thomas K. Eigentler
Piotr Rutkowski
Lev V. Demidov
Georgy M. Manikhas
Sara Tadesse-Bell
Kuan-Chieh Huang
V. McNally
Sohail Mulla
Grant A. McArthur
Ralf Gutzmer
Show All
Source
Cite
Save
Citations (0)
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
2020
Journal of Clinical Oncology
Peter R. Galle
Richard S. Finn
Shukui Qin
Masafumi Ikeda
Andrew X. Zhu
Tae-You Kim
Masatoshi Kudo
V V Breder
Philippe Merle
Ahmed Omar Kaseb
Daneng Li
Sohail Mulla
Wendy Verret
Derek-Zhen Xu
Sairy Hernandez
Juan Liu
Chen Huang
Ho Yeong Lim
Ann-Lii Cheng
Michel Ducreux
Show All
Source
Cite
Save
Citations (20)
1